WO2004022593A8 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Google Patents
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid moleculesInfo
- Publication number
- WO2004022593A8 WO2004022593A8 PCT/IB2003/004347 IB0304347W WO2004022593A8 WO 2004022593 A8 WO2004022593 A8 WO 2004022593A8 IB 0304347 W IB0304347 W IB 0304347W WO 2004022593 A8 WO2004022593 A8 WO 2004022593A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytokines
- nucleic acid
- acid molecules
- encoding nucleic
- higher stability
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT03794017T ATE466085T1 (en) | 2002-09-09 | 2003-09-08 | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES |
EP03794017A EP1539960B1 (en) | 2002-09-09 | 2003-09-08 | Protease-resistant modified interferon alpha polypeptides |
CA002498319A CA2498319A1 (en) | 2002-09-09 | 2003-09-08 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
AU2003263552A AU2003263552A1 (en) | 2002-09-09 | 2003-09-08 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
DE60332358T DE60332358D1 (en) | 2002-09-09 | 2003-09-08 | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40989802P | 2002-09-09 | 2002-09-09 | |
US60/409,898 | 2002-09-09 | ||
US45713503P | 2003-03-21 | 2003-03-21 | |
US60/457,135 | 2003-03-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004022593A2 WO2004022593A2 (en) | 2004-03-18 |
WO2004022593A3 WO2004022593A3 (en) | 2004-07-15 |
WO2004022593A8 true WO2004022593A8 (en) | 2007-05-18 |
Family
ID=31981642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/004347 WO2004022593A2 (en) | 2002-09-09 | 2003-09-08 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
Country Status (8)
Country | Link |
---|---|
US (12) | US7611700B2 (en) |
EP (1) | EP1539960B1 (en) |
AT (1) | ATE466085T1 (en) |
AU (1) | AU2003263552A1 (en) |
CA (1) | CA2498319A1 (en) |
DE (1) | DE60332358D1 (en) |
ES (1) | ES2343518T3 (en) |
WO (1) | WO2004022593A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7884073B2 (en) | 2004-11-04 | 2011-02-08 | Hanall Biopharma Co., Ltd. | Modified growth hormone |
US8052964B2 (en) | 2002-09-09 | 2011-11-08 | Hanall Biopharma Co., Ltd. | Interferon-β mutants with increased anti-proliferative activity |
US8252743B2 (en) | 2006-11-28 | 2012-08-28 | Hanall Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
JP7050007B2 (en) | 2016-06-08 | 2022-04-07 | ヤンセン バイオテツク,インコーポレーテツド | GM-CSF mutant and usage |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2808804B1 (en) * | 2000-05-09 | 2002-08-02 | Nautilus Biotech | METHOD FOR DETERMINING THE TITLE OF BIOLOGICAL AGENTS IN REAL TIME IN LIVING TARGET CELLS AND ITS APPLICATIONS |
US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
NZ537306A (en) * | 2002-07-01 | 2008-11-28 | Kenneth S Warren Inst Inc | Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier |
US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20050054053A1 (en) * | 2002-10-01 | 2005-03-10 | Xencor, Inc. | Interferon variants with improved properties |
EP1581631A4 (en) * | 2002-10-01 | 2007-09-05 | Xencor Inc | Interferon variants with improved properties |
KR20100109969A (en) * | 2002-10-02 | 2010-10-11 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | Methods of generating and screening for proteases with altered specificity |
US7456257B2 (en) * | 2003-02-18 | 2008-11-25 | Merck Patent Gmbh | Fusion proteins of interferon alpha muteins with improved properties |
WO2006076014A2 (en) * | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
KR20070085227A (en) * | 2004-08-09 | 2007-08-27 | 앨리오스 바이오파마 인크. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
WO2006029094A2 (en) * | 2004-09-02 | 2006-03-16 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
US7211973B1 (en) * | 2005-01-07 | 2007-05-01 | Marvell Asia Pte, Ltd. | System and process for utilizing back electromotive force in disk drives |
AU2005325768A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
WO2006111745A2 (en) * | 2005-04-20 | 2006-10-26 | Viragen Incorporated | Composition and method for treating viral infection |
CA2607806A1 (en) * | 2005-05-04 | 2006-11-16 | Nautilus Biotech, S.A. | Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides |
CN101257925A (en) * | 2005-06-20 | 2008-09-03 | 派普根公司 | Low-toxicity, long-circulating chimeras of human interferon-alpha analogs and interferon tau |
EP2476428B1 (en) * | 2005-06-29 | 2013-08-21 | Yeda Research and Development Co. Ltd. | Recombinant interferon alpha 2 (IFN alpha 2) mutants |
WO2007098547A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
WO2007098548A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
EP2581450B1 (en) | 2006-05-02 | 2018-08-15 | MedImmune Limited | Non-natural amino acid substituted polypeptides |
US20080096819A1 (en) | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
EP2084274A2 (en) | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
AR078117A1 (en) * | 2006-06-20 | 2011-10-19 | Protech Pharma S A | A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE |
FR2905375A1 (en) * | 2006-08-29 | 2008-03-07 | Biomethodes Sa | Thermostable variants of human interferon alpha useful for preparing antiviral, antiproliferative or immunomodulatory medicaments have one or more selected amino acid substitutions |
ES2606034T3 (en) | 2006-09-28 | 2017-03-17 | Merck Sharp & Dohme Corp. | Pegylated IL-10 for use in the treatment of lymphoma |
CN101553499B (en) | 2006-10-10 | 2013-10-16 | 澳大利亚国立大学 | Process for generation of protein and uses thereof |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
ATE548381T1 (en) * | 2008-05-29 | 2012-03-15 | Hanall Biopharma Co Ltd | MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES WITH INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF |
KR20110039348A (en) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Conjugated proteins with prolonged in vivo efficacy |
CN103601800B (en) | 2008-12-17 | 2015-10-21 | 默沙东公司 | The production of single and double PEG IL10 and purposes |
WO2010085086A2 (en) * | 2009-01-20 | 2010-07-29 | 한올바이오파마 주식회사 | Modified human thrombopoietin polypeptide fragment and manufacturing method thereof |
KR20110122100A (en) | 2009-01-22 | 2011-11-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Stable growth hormone compounds |
US8940501B2 (en) | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
SG176000A1 (en) * | 2009-05-13 | 2011-12-29 | Protein Delivery Solutions Llc | Pharmaceutical system for trans-membrane delivery |
US20100310509A1 (en) * | 2009-06-04 | 2010-12-09 | Ash John D | COMPOSITIONS COMPRISING MODULATORS OF SIGNAL TRANSDUCING RECEPTOR gp130 AND METHODS OF PRODUCING AND USING SAME |
EP2461831B1 (en) | 2009-08-06 | 2018-11-21 | Novo Nordisk Health Care AG | Growth hormones with prolonged in-vivo efficacy |
JP5980689B2 (en) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Stable growth hormone compound |
CN102834109B (en) | 2010-01-22 | 2016-01-20 | 诺沃—诺迪斯克保健股份有限公司 | Stable growth hormone compound |
EP2595661A1 (en) | 2010-07-22 | 2013-05-29 | Novo Nordisk Health Care AG | Growth hormone conjugates |
CN103547288B (en) | 2011-01-10 | 2016-03-16 | 密执安大学评议会 | Stem cell factor inhibitor |
US9732132B2 (en) * | 2011-01-14 | 2017-08-15 | Vanderbilt University | Therapeutic compositions and methods for disorders associated with neuronal degeneration |
CN103764665A (en) | 2011-06-28 | 2014-04-30 | 怀特黑德生物医学研究所 | Using sortases to install click chemistry handles for protein ligation |
JP6184965B2 (en) | 2011-10-28 | 2017-08-23 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Polypeptide constructs and uses thereof |
BR112015024423B1 (en) * | 2013-03-29 | 2023-04-25 | Glytech, Inc | GLYCOSYLATED POLYPEPTIDE HAVING INTERFERON ACTIVITY, PHARMACEUTICAL COMPOSITION AND USE OF A GLYCOSYLATED POLYPEPTIDE |
JP6464145B2 (en) | 2013-04-05 | 2019-02-06 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Growth hormone compound preparation |
CN105209054A (en) | 2013-04-18 | 2015-12-30 | 阿尔莫生物科技股份有限公司 | Methods of using interleukin-10 for treating diseases and disorders |
US20160068583A1 (en) * | 2013-04-24 | 2016-03-10 | Armo Biosciences, Inc. | Interleukin-10 Compositions and Uses Thereof |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
WO2015006554A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
WO2015031316A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
KR20160079114A (en) | 2013-11-11 | 2016-07-05 | 아르모 바이오사이언시스 인코포레이티드 | Methods of using interleukin-10 for treating diseases and disorders |
KR102230547B1 (en) * | 2013-11-13 | 2021-03-22 | 수퍼랩 파 이스트 리미티드 | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
MX2017004838A (en) | 2014-10-14 | 2017-10-16 | Armo Biosciences Inc | Interleukin-15 compositions and uses thereof. |
EP3209320B1 (en) | 2014-10-22 | 2023-03-08 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
EP3212216A4 (en) | 2014-10-29 | 2018-04-18 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha2b variants |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CN107847564B (en) | 2015-05-12 | 2021-11-09 | 远东超级实验室有限公司 | Method for identifying interferon with direct inhibition effect on tumor and application thereof |
EP3302547A1 (en) | 2015-05-28 | 2018-04-11 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
JP7053453B2 (en) | 2015-08-25 | 2022-04-12 | アルモ・バイオサイエンシーズ・インコーポレイテッド | How to use interleukin 10 to treat diseases and disorders |
CA3019005A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
IL297617B2 (en) | 2016-12-22 | 2023-11-01 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
CN110520436A (en) | 2017-03-15 | 2019-11-29 | 潘迪恩治疗公司 | Target immunological tolerance |
JP2020514375A (en) | 2017-03-15 | 2020-05-21 | キュー バイオファーマ, インコーポレイテッド | Methods for modulating the immune response |
US10926283B2 (en) | 2017-04-12 | 2021-02-23 | Carolyn S. Jordan | Fingertip mist |
EP3630163A4 (en) * | 2017-05-24 | 2021-06-09 | Pandion Operations, Inc. | Targeted immunotolerance |
WO2019073315A1 (en) | 2017-10-09 | 2019-04-18 | Mansour Poorebrahim | Interferon-beta analog peptide |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
EP3720871A4 (en) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | Targeted immunotolerance |
EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
MX2021000801A (en) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Il2 agonists. |
CN113166261A (en) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7H3 single domain antibodies and therapeutic compositions thereof |
JP2022504822A (en) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | DLL3 single domain antibody and therapeutic composition thereof |
WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
CA3169564A1 (en) | 2020-03-31 | 2021-10-07 | Hanmi Pharm. Co., Ltd. | Novel immunostimulating il-2 analogs |
IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of use thereof |
Family Cites Families (308)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US134351A (en) * | 1872-12-31 | Improvement in crutches | ||
US129584A (en) * | 1872-07-16 | Improvement in springs for gates and doors | ||
US129203A (en) * | 1872-07-16 | Improvement in animal-traps | ||
US175694A (en) * | 1876-04-04 | Improvement in sponge-cups | ||
US3171820A (en) | 1964-02-17 | 1965-03-02 | Scott Paper Co | Reticulated polyurethane foams and process for their production |
US3224404A (en) * | 1964-11-06 | 1965-12-21 | Jong George E De | Mooring device |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4302386A (en) * | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US4363877B1 (en) * | 1977-09-23 | 1998-05-26 | Univ California | Recombinant dna transfer vectors |
US5221619A (en) * | 1977-11-08 | 1993-06-22 | Genentech, Inc. | Method and means for microbial polypeptide expression |
US4503035B1 (en) | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
US4898830A (en) * | 1979-07-05 | 1990-02-06 | Genentech, Inc. | Human growth hormone DNA |
US5510472A (en) * | 1979-11-21 | 1996-04-23 | Yeda Research And Development Co. Ltd. | Production of recombinant human interferon-beta2 |
US4816396A (en) * | 1980-03-10 | 1989-03-28 | Cetus Corporation | Method and vector organism for controlled accumulation of heterologous gene products in bacillus subtilis |
US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
US4462985A (en) | 1980-08-22 | 1984-07-31 | University Of Illinois Foundation | Delivery of biologically active components of heterologous species interferon isolates |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4775622A (en) * | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
US4670393A (en) * | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
US4446235A (en) * | 1982-03-22 | 1984-05-01 | Genentech, Inc. | Method for cloning human growth hormone varient genes |
US4665160A (en) * | 1982-03-22 | 1987-05-12 | Genentech, Inc. | Novel human growth hormone like protein HGH-V encoded in the human genome |
DE3220116A1 (en) | 1982-05-28 | 1983-12-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | MICROBIOLOGICALLY MANUFACTURED (ALPHA) AND SS INTERFERONES, DNA SEQUENCES CODING FOR THESE INTERFERONES, MICROORGANISMS CONTAINING THIS GENETIC INFORMATION, AND METHOD FOR THE PRODUCTION THEREOF |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US5618697A (en) * | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
US4820515A (en) | 1982-12-13 | 1989-04-11 | Texas A&M University System | Method of using interferon in low dosage to regulate appetite and efficiency of food utilization |
US4497795A (en) | 1982-12-13 | 1985-02-05 | The Texas A&M University System | Method of regulating appetite and efficiency of food utilization employing interferon |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4755465A (en) * | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
US4859600A (en) * | 1983-04-25 | 1989-08-22 | Genentech, Inc. | Recombinant procaryotic cell containing correctly processed human growth hormone |
GB8317880D0 (en) * | 1983-07-01 | 1983-08-03 | Searle & Co | Structure and synthesis of interferons |
US5256546A (en) * | 1983-07-15 | 1993-10-26 | Bio-Technology General Corp. | Bacterial expression of porcine growth hormone |
US5637495A (en) * | 1983-07-15 | 1997-06-10 | Bio-Technology General Corp. | Plasmids for production of human growth hormone or polypeptide analog thereof, hosts containing the plasmids, products manufactured thereby, and related methods |
BG49718A3 (en) * | 1983-07-15 | 1992-01-15 | Bio Technology General Corp | Method for preparing of polypeptid with superoxiddismutasne activitty |
US5198361A (en) * | 1983-07-15 | 1993-03-30 | Bio-Technology General Corp. | Plasmids for production of met-asp-gln bovine growth hormone, hosts containing the plasmids, products manufactured thereby and related methods |
US5670371A (en) * | 1983-07-15 | 1997-09-23 | Bio-Technology General Corp. | Bacterial expression of superoxide dismutase |
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
KR850004274A (en) * | 1983-12-13 | 1985-07-11 | 원본미기재 | Method for preparing erythropoietin |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
GB8412564D0 (en) * | 1984-05-17 | 1984-06-20 | Searle & Co | Structure and properties |
US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
US4937076A (en) * | 1984-08-10 | 1990-06-26 | Combe Incorporated | Chewable aspirin and buffering material tablet and method for producing same |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
US5198345A (en) | 1985-04-15 | 1993-03-30 | Gist-Brocades N.V. | Vectors in use in filamentous fungi |
US4845196A (en) * | 1985-06-24 | 1989-07-04 | G. D. Searle & Co. | Modified interferon gammas |
US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5631227A (en) * | 1985-09-18 | 1997-05-20 | The Upjohn Company | Somatotropin analogs |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
IL77186A0 (en) * | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
US5298603A (en) * | 1985-12-21 | 1994-03-29 | Hoechst Aktiengesellschaft | GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use |
US4820514A (en) | 1985-12-30 | 1989-04-11 | Texas A&M University System | Low dosage of interferon to enhance vaccine efficiency |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
EP0240224A3 (en) * | 1986-03-31 | 1989-02-01 | Interferon Sciences, Inc. | An alpha interferon analogue |
US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
DK173067B1 (en) * | 1986-06-27 | 1999-12-13 | Univ Washington | Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines |
DE3683910D1 (en) | 1986-09-05 | 1992-03-26 | Cetus Corp | OXIDATION RESISTANT MUTEINE FROM BETA-INTERFERON, THEIR PRODUCTION AND THE PREPARATIONS CONTAINING THESE MUTEINE. |
US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
ZA878295B (en) | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
US5013718A (en) * | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
US5214132A (en) * | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5017371A (en) | 1988-01-06 | 1991-05-21 | Amarillo Cell Culture Company, Incorporated | Method for reducing side effects of cancer therapy |
US5622845A (en) * | 1988-02-17 | 1997-04-22 | The Upjohn Company | Fermentation method for producing norleucine |
US5068317A (en) * | 1988-03-15 | 1991-11-26 | Eli Lilly And Company | Novel derivative of human growth hormone |
US5445826A (en) * | 1988-06-28 | 1995-08-29 | Cibus Pharmaceutical, Inc. | Delivery system containing a gel-forming dietary fiber and a drug |
CA1333777C (en) * | 1988-07-01 | 1995-01-03 | Randy M. Berka | Aspartic proteinase deficient filamentous fungi |
US5079345A (en) * | 1988-08-19 | 1992-01-07 | Eli Lilly And Company | Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism |
ES2154627T3 (en) * | 1988-08-24 | 2001-04-16 | American Cyanamid Co | STABILIZATION OF SOMATOTROPINS THROUGH THE MODIFICATION OF CISTEINE REMAINS USING DIRECTED LOCATION OR CHEMICAL DERIVATIZATION MUTAGENESIS. |
US5130422A (en) * | 1988-08-29 | 1992-07-14 | Monsanto Company | Variant somatotropin-encoding DNA |
US5089473A (en) * | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5079230A (en) * | 1988-09-12 | 1992-01-07 | Pitman-Moore, Inc. | Stable bioactive somatotropins |
GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
WO1990004788A1 (en) * | 1988-10-28 | 1990-05-03 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5688666A (en) * | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5101018A (en) * | 1989-06-12 | 1992-03-31 | International Minerals & Chemical Corp. | Method for recovering recombinant proteins |
US5663305A (en) * | 1989-07-10 | 1997-09-02 | The Upjohn Company | Somatotropin analogs |
DE3923963A1 (en) * | 1989-07-20 | 1991-01-31 | Behringwerke Ag | MUTEINE OF HUMAN ERYTHROPOETIN, THEIR PRODUCTION AND THEIR USE |
US5047511A (en) * | 1989-08-28 | 1991-09-10 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5958879A (en) * | 1989-10-12 | 1999-09-28 | Ohio University/Edison Biotechnology Institute | Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal |
US6787336B1 (en) * | 1989-10-12 | 2004-09-07 | Ohio University/Edison Biotechnology Institute | DNA encoding growth hormone antagonists |
US6583115B1 (en) * | 1989-10-12 | 2003-06-24 | Ohio University/Edison Biotechnology Institute | Methods for treating acromegaly and giantism with growth hormone antagonists |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
JPH03151399A (en) | 1989-11-07 | 1991-06-27 | Snow Brand Milk Prod Co Ltd | Mutant human erythropoietin |
CA2072587A1 (en) * | 1990-01-08 | 1991-07-09 | Gail F. Seelig | Oxidized variants of gm-csf |
US5109121A (en) * | 1990-01-22 | 1992-04-28 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US4988798A (en) * | 1990-01-22 | 1991-01-29 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US5262568A (en) | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
EP0527809B1 (en) | 1990-04-05 | 1995-08-16 | CREA, Roberto | Walk-through mutagenesis |
GB9107846D0 (en) * | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
US5951972A (en) * | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
US5399345A (en) * | 1990-05-08 | 1995-03-21 | Boehringer Mannheim, Gmbh | Muteins of the granulocyte colony stimulating factor |
HUT63185A (en) | 1990-06-04 | 1993-07-28 | Schering Corp | Process for producing crystalline alpha-2-interferon |
US5849694A (en) * | 1990-07-16 | 1998-12-15 | Synenki; Richard M. | Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US6258530B1 (en) | 1990-09-28 | 2001-07-10 | Ixsys, Inc. | Surface expression libraries of randomized peptides |
US5871974A (en) | 1990-09-28 | 1999-02-16 | Ixsys Inc. | Surface expression libraries of heteromeric receptors |
US5215741A (en) | 1990-10-30 | 1993-06-01 | Amarillo Cell Culture Company, Incorporated | Method for prevention of parasite infections |
CA2044468C (en) * | 1990-11-21 | 2006-08-22 | Richard A. Nash | Canine granulocyte macrophage colony stimulating factor |
US5310882A (en) * | 1990-11-30 | 1994-05-10 | American Cyanamid Company | Somatotropins with alterations in the α-helix 3 region |
NZ240718A (en) * | 1990-11-30 | 1996-10-28 | Bio Technology General Corp | Somatotropin analogues carrying mutations in the alpha-helix-1 region |
WO1992009690A2 (en) * | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
EP0499990B1 (en) * | 1991-02-19 | 1996-05-15 | Takeda Chemical Industries, Ltd. | Method for producing cysteine-free peptides |
JP3417558B2 (en) * | 1991-05-10 | 2003-06-16 | ジェネンテク,インコーポレイテッド | Choice of ligand agonists and antagonists |
US5733761A (en) * | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
JPH05289267A (en) * | 1992-04-07 | 1993-11-05 | Fuji Photo Film Co Ltd | Silver halide color photographic sensitive material |
US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US6436387B1 (en) * | 1992-11-24 | 2002-08-20 | G.D. Searle & Co. | Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
CN1125401A (en) * | 1993-04-29 | 1996-06-26 | 艾博特公司 | Erythropoietin analog compositions and methods |
EP0626448A3 (en) | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Process for preparing and purifying alpha-interferon |
US5789551A (en) | 1993-06-11 | 1998-08-04 | Pestka Biomedical Laboratories, Inc. | Human leukocyte interferon Hu-IFN-α001 |
US6299870B1 (en) | 1993-06-11 | 2001-10-09 | Pbl Biomedical Laboratories | Mutant human interferons |
NZ269766A (en) * | 1993-07-28 | 1998-01-26 | Medvet Science Pty Ltd | Haemopoietic growth factor antagonists; relates to modified forms of such factors |
US5424289A (en) * | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
US5798500A (en) * | 1993-08-10 | 1998-08-25 | Stillwagon, Jr.; Ross I. | Curling iron stove with internal cavity with electric heater positioned therebelow |
CN1057534C (en) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | Erythropoietin analogs |
US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
EP0749980A4 (en) * | 1993-12-29 | 1999-09-29 | Sumitomo Pharma | Novel human ciliary neurotrophic factor |
US5597709A (en) * | 1994-01-27 | 1997-01-28 | Human Genome Sciences, Inc. | Human growth hormone splice variants hGHV-2(88) and hGHV-3(53) |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
KR100403688B1 (en) * | 1994-02-23 | 2004-02-05 | 교와 핫꼬 고교 가부시끼가이샤 | Thrombocytopenia and pharmaceutical compositions comprising the same |
EP0748338A4 (en) | 1994-03-04 | 2001-03-28 | Merck & Co Inc | In vitro antibody affinity maturation using alanine scanning mutagenesis |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US6024734A (en) | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US6346243B1 (en) | 1994-04-12 | 2002-02-12 | Research Development Foundation | Inhibition of transplant rejection by type one interferon |
JP3560639B2 (en) | 1994-05-26 | 2004-09-02 | 株式会社タカハシキカン | Incinerator |
FR2722208B1 (en) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE |
US5460232A (en) * | 1994-07-25 | 1995-10-24 | Central Mine Equipment Company | Rotary earth drill bit socket shield |
US6099830A (en) * | 1994-08-09 | 2000-08-08 | Zymogenetics, Inc. | Methods for stimulating erythropoiesis using hematopoietic proteins |
IL116085A (en) * | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US5814485A (en) * | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
US5871723A (en) | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
US5854049A (en) * | 1995-06-09 | 1998-12-29 | President And Fellows Of Harvard College | Plasmin-resistant streptokinase |
AUPN378095A0 (en) * | 1995-06-23 | 1995-07-20 | Bresagen Limited | Haemopoietic growth factor antagonists and uses therefor |
NZ286884A (en) * | 1995-06-29 | 1997-12-19 | Mitsui Chemicals Inc | Use of 20 kd human growth hormone in hrt, increasing serum igf-1 levels and stimulating lipolysis |
US6057103A (en) | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
DE19535853C2 (en) * | 1995-09-18 | 1999-04-01 | Fraunhofer Ges Forschung | Variants of recombinant human interferon gamma, process for their preparation and their use |
ATE455171T1 (en) * | 1995-09-21 | 2010-01-15 | Genentech Inc | VARIANTS OF HUMAN GROWTH HORMONE |
EP0858343B1 (en) | 1995-11-02 | 2004-03-31 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US20030215798A1 (en) | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
CA2244372A1 (en) | 1996-01-23 | 1997-07-31 | Marc S. Collett | Methods for identifying inhibitors of rna viruses |
DE69712124T2 (en) * | 1996-02-13 | 2002-12-12 | Jcr Pharmaceutical Co | Hormones de croissance humaines mutantes et leur utilization |
GEP20012489B (en) | 1996-02-28 | 2001-07-25 | Ifi Inst Farmacoterapico Italiano S P A | Use of Natural Human α-Interferon |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
SI9720025A (en) * | 1996-03-29 | 1999-08-31 | Emishphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6204022B1 (en) | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
WO1997041884A1 (en) | 1996-05-09 | 1997-11-13 | Pharma Pacific Pty. Ltd. | Method of treatment |
CN1151840C (en) | 1996-05-09 | 2004-06-02 | 太平洋制药控股公司 | Stimulation of host defence mechanisms against tumors |
US6207145B1 (en) | 1997-05-09 | 2001-03-27 | Pharma Pacific Pty Ltd. | Therapeutic applications of high dose interferon |
US5763239A (en) | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
WO1998007878A2 (en) * | 1996-08-23 | 1998-02-26 | Arch Development Corporation | Long-term expression of gene products by transforming muscle cells |
JP2001504325A (en) | 1996-09-27 | 2001-04-03 | マキシジェン,インコーポレイテッド | A method for optimization of gene therapy by recursive sequence shuffling and selection |
US6967092B1 (en) * | 1996-10-25 | 2005-11-22 | Mc Kearn John P | Multi-functional chimeric hematopoietic receptor agonists |
DE19648625A1 (en) * | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Microprojectile for the introduction of substances into cells by ballistic transfer |
US5862514A (en) | 1996-12-06 | 1999-01-19 | Ixsys, Inc. | Method and means for synthesis-based simulation of chemicals having biological functions |
BR9606270A (en) * | 1996-12-18 | 1998-09-22 | Univ Minas Gerais | Process for the production of recombinant human beta-cis interferon protein and recombinant human beta-cis interferon protein |
US6884419B1 (en) * | 1996-12-23 | 2005-04-26 | Kyowa Hakko Kogyo, Co., Ltd. | hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same |
US5779434A (en) | 1997-02-06 | 1998-07-14 | Baker Hughes Incorporated | Pump mounted thrust bearing |
DE19717864C2 (en) | 1997-04-23 | 2001-05-17 | Fraunhofer Ges Forschung | Human recombinant interferon beta, process for its preparation and its use |
US6153420A (en) * | 1997-04-24 | 2000-11-28 | Zymogenetics, Inc. | Serine protease polypeptides and materials and methods for making them |
WO1998050025A1 (en) * | 1997-05-08 | 1998-11-12 | Chugai Seiyaku Kabushiki Kaisha | Preventives/remedies for arteriosclerosis |
AU7383298A (en) * | 1997-05-13 | 1998-12-08 | Regents Of The University Of California, The | Novel antiangiogenic peptide agents and their therapeutic and diagnostic use |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
BR9812267B1 (en) * | 1997-07-14 | 2013-11-26 | Recombinant Growth Hormone. | |
US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
DE69838647T2 (en) * | 1997-09-08 | 2008-08-28 | Metabolic Pharmaceuticals Ltd., Melbourne | TREATMENT OF GRAVITY |
US6156509A (en) | 1997-11-12 | 2000-12-05 | Genencor International, Inc. | Method of increasing efficiency of directed evolution of a gene using phagemid |
US6897297B1 (en) | 1997-12-03 | 2005-05-24 | Curis, Inc. | Hydrophobically-modified protein compositions and methods |
US6165458A (en) | 1997-12-26 | 2000-12-26 | Pharmaderm Laboratories Ltd. | Composition and method for dermal and transdermal administration of a cytokine |
US6274158B1 (en) * | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
DE69825137T2 (en) * | 1998-02-23 | 2005-07-21 | Cilag Ag International | Liposomal erythropoietin dispersion |
US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
US6676937B1 (en) * | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
US20040228834A1 (en) * | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
US6174406B1 (en) * | 1998-04-09 | 2001-01-16 | International Business Machines Corporation | Bonding together surfaces |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US6548653B1 (en) * | 1998-06-15 | 2003-04-15 | Genzyme Transgenics Corporation | Erythropoietin analog-human serum albumin fusion |
US6472512B1 (en) * | 1998-07-21 | 2002-10-29 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
EE04967B1 (en) * | 1998-10-16 | 2008-02-15 | Biogen, Incorporated | Glycylated Interferon Beta, its Use and a Pharmaceutical Composition, Method for Prolonging Interferon Beta-1a Activity, and Preparing a Protein of the Invention |
MXPA01003790A (en) * | 1998-10-16 | 2002-09-18 | Biogen Inc | Interferon-beta fusion proteins and uses. |
AUPP660698A0 (en) * | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
CA2352167A1 (en) | 1998-11-25 | 2000-06-08 | Amarillo Biosciences, Inc. | Interferon-alpha mediated upregulation of aquaporin expression |
JP2002531089A (en) * | 1998-11-30 | 2002-09-24 | イーライ・リリー・アンド・カンパニー | Erythropoietic compounds |
US6171620B1 (en) * | 1999-04-27 | 2001-01-09 | Health Research, Inc. | Method of enhancing the efficacy of anti-tumor agents |
US6555343B1 (en) * | 1999-05-07 | 2003-04-29 | Genentech Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
US6831060B2 (en) * | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
US6946265B1 (en) * | 1999-05-12 | 2005-09-20 | Xencor, Inc. | Nucleic acids and proteins with growth hormone activity |
US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
US6710025B1 (en) * | 1999-05-26 | 2004-03-23 | The Brigham And Women's Hospital, Inc. | Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin |
US6319691B1 (en) * | 1999-06-15 | 2001-11-20 | Usa Universe Bioengineering, Inc. | Fusion proteins comprising IFN-alpha2b and TM-alpha1 |
US6566329B1 (en) * | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
CZ299516B6 (en) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
KR100356140B1 (en) * | 1999-07-08 | 2002-10-19 | 한미약품공업 주식회사 | Modified Human Granulocyte-Colony Stimulating Factor and Process for Producing Same |
US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
AU7731700A (en) | 1999-09-28 | 2001-04-30 | Amarillo Biosciences, Inc. | Low dose ifn-gamma for treatment of disease |
WO2001025438A2 (en) * | 1999-10-07 | 2001-04-12 | Maxygen, Inc. | Ifn-alpha homologues |
US20040002474A1 (en) | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
AU1436401A (en) | 1999-10-21 | 2001-05-14 | Board Of Trustees Of The University Of Arkansas, The | RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof |
AU7646200A (en) | 1999-11-05 | 2001-05-14 | Novozymes A/S | Microtiter plate (mtp) based high throughput screening (hts) assays |
KR20020065517A (en) * | 1999-11-12 | 2002-08-13 | 맥시겐 홀딩스 리미티드 | Interferon gamma conjugates |
DE60021760T2 (en) | 1999-12-09 | 2006-06-08 | Chiron Corp., Emeryville | METHOD FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES IN THE CENTRAL NERVOUS SYSTEM OR LYMPHIC SYSTEM |
FR2802645B1 (en) | 1999-12-16 | 2002-03-08 | Meillat Roland | METHOD FOR EVALUATING THE PERFORMANCE OF A SET OF BIOLOGICAL AGENTS IN LIVE TARGET CELLS AND ITS APPLICATIONS |
US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
WO2001061344A1 (en) * | 2000-02-17 | 2001-08-23 | California Institute Of Technology | Computationally targeted evolutionary design |
AU780270B2 (en) * | 2000-02-23 | 2005-03-10 | Association Francaise Contre Les Myopathies | Treatment of immune diseases |
FR2808804B1 (en) | 2000-05-09 | 2002-08-02 | Nautilus Biotech | METHOD FOR DETERMINING THE TITLE OF BIOLOGICAL AGENTS IN REAL TIME IN LIVING TARGET CELLS AND ITS APPLICATIONS |
AU2001256499B2 (en) * | 2000-05-12 | 2007-07-26 | University College Cardiff Consultants Limited | Method for detecting growth hormone variations in humans, the variations and their uses |
ATE367398T1 (en) * | 2000-05-16 | 2007-08-15 | Bolder Biotechnology Inc | METHOD FOR REFOLDING PROTEINS WITH FREE CYSTEINE RESIDUE |
US7154958B2 (en) * | 2000-07-05 | 2006-12-26 | Texas Instruments Incorporated | Code division multiple access wireless system with time reversed space time block transmitter diversity |
DE60142971D1 (en) | 2000-07-31 | 2010-10-14 | Biolex Therapeutics Inc | EXPRESSION OF BIOLOGICALLY ACTIVE POLYPEPTIDES IN WATER LENS |
JP4707931B2 (en) | 2000-08-18 | 2011-06-22 | エミスフェアー・テクノロジーズ・インク | Active agent delivery compounds and compositions |
WO2002015664A2 (en) | 2000-08-23 | 2002-02-28 | The New York Hospital Medical Center Of Queens | Methods of preventing or treating west nile virus and other infections |
FR2813314B1 (en) | 2000-08-25 | 2004-05-07 | Biomethodes | MASSIVE DIRECTED MUTAGENESIS PROCESS |
MXPA03002046A (en) * | 2000-09-08 | 2003-07-24 | Massachusetts Inst Technology | G-csf analog compositions and methods. |
US20020169290A1 (en) * | 2000-11-02 | 2002-11-14 | Claus Bornaes | New multimeric interferon beta polypeptides |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
HUP0400703A3 (en) * | 2001-02-06 | 2006-06-28 | Merck Patent Gmbh | Modified erythropoietin (epo) with reduced immunogenicity |
CN1514844A (en) * | 2001-02-06 | 2004-07-21 | Ĭ��ר������˾ | Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity |
MXPA03007323A (en) * | 2001-02-19 | 2003-12-12 | Merck Patent Gmbh | Artificial proteins with reduced immunogenicity. |
MXPA03008032A (en) * | 2001-03-08 | 2003-12-04 | Merck Patent Gmbh | Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity. |
BR0208041A (en) * | 2001-03-15 | 2004-02-25 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
FR2823220B1 (en) * | 2001-04-04 | 2003-12-12 | Genodyssee | NOVEL ERYTHROPOIETIN (EPO) POLYNUCLEOTIDES AND POLYPEPTIDES |
US7271150B2 (en) * | 2001-05-14 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified growth hormone |
US6833351B2 (en) * | 2001-05-21 | 2004-12-21 | Douglas T. Dieterich | Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US20030129203A1 (en) | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
MXPA04001976A (en) * | 2001-09-04 | 2004-06-07 | Merck Patent Gmbh | Modified human growth hormone. |
US6688666B2 (en) * | 2001-09-13 | 2004-02-10 | Colin G. Neale | Second row fold and pivot seat assembly |
US6930086B2 (en) * | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
US7297511B2 (en) | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
EP1507540A4 (en) * | 2001-10-10 | 2006-12-06 | Centocor Inc | Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid |
US6786634B2 (en) * | 2001-10-10 | 2004-09-07 | Noritake Co., Limited | Temperature measuring method and apparatus |
CN101724075B (en) * | 2001-10-10 | 2014-04-30 | 诺和诺德公司 | Remodeling and glycoconjugation of peptides |
CA2466346A1 (en) * | 2001-11-09 | 2003-05-22 | Pharmacia & Upjohn Company | Single nucleotide polymorphisms in gh-1 |
GB0127213D0 (en) * | 2001-11-12 | 2002-01-02 | Univ Wales Medicine | Method of detecting growth hormone variations in humans the variations and their uses |
GB2389115B (en) * | 2001-12-14 | 2005-03-16 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone |
US20030224404A1 (en) | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
NZ537306A (en) | 2002-07-01 | 2008-11-28 | Kenneth S Warren Inst Inc | Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier |
US6809191B2 (en) * | 2002-07-03 | 2004-10-26 | Vaxim, Inc. | GM-CSF nucleic acid sequences |
BR0313135A (en) * | 2002-08-09 | 2005-07-05 | Merck Patent Gmbh | T cell epitopes in erythropoietin |
EP1549675B1 (en) | 2002-08-31 | 2008-02-13 | CJ Corp | Glycosylated human interferon alpha isoform |
US7611700B2 (en) * | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20050176627A1 (en) * | 2002-09-09 | 2005-08-11 | Anthony Cerami | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
WO2004022747A1 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20050202438A1 (en) | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
EP1581631A4 (en) | 2002-10-01 | 2007-09-05 | Xencor Inc | Interferon variants with improved properties |
US20050054053A1 (en) * | 2002-10-01 | 2005-03-10 | Xencor, Inc. | Interferon variants with improved properties |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20040091961A1 (en) * | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
KR20050086498A (en) | 2002-11-18 | 2005-08-30 | 맥시겐, 인크. | Interferon-alpha polypeptides and conjugates |
TWI281864B (en) * | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
KR100541850B1 (en) | 2003-03-31 | 2006-01-11 | 삼성정밀화학 주식회사 | Mutein of human interferon-beta and its preparation method |
EP1636256A2 (en) | 2003-06-10 | 2006-03-22 | Xencor, Inc. | Interferon variants with improved properties |
KR100632985B1 (en) * | 2003-07-26 | 2006-10-11 | 메덱스젠 주식회사 | A method of improving efficacy of biological response-modifying proteins and the example muteins |
CA2552892C (en) * | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
NZ586034A (en) * | 2004-02-02 | 2011-10-28 | Ambrx Inc | Modified human growth hormone polypeptides and their uses |
JP2008508854A (en) | 2004-04-23 | 2008-03-27 | ケンブリッジ アンティボディー テクノロジー リミテッド | Erythropoietin protein variant |
CA2565368A1 (en) * | 2004-04-29 | 2005-11-24 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases |
KR20070085227A (en) | 2004-08-09 | 2007-08-27 | 앨리오스 바이오파마 인크. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
WO2006029094A2 (en) | 2004-09-02 | 2006-03-16 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
WO2006024547A2 (en) | 2004-09-03 | 2006-03-09 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
GB0500099D0 (en) | 2005-01-05 | 2005-02-09 | Cambridge Antibody Tech | Methods and means relating to protein variants |
CA2607806A1 (en) * | 2005-05-04 | 2006-11-16 | Nautilus Biotech, S.A. | Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides |
WO2007110230A2 (en) | 2006-03-27 | 2007-10-04 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
EP2084274A2 (en) * | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
EP2120998B1 (en) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
ATE548381T1 (en) | 2008-05-29 | 2012-03-15 | Hanall Biopharma Co Ltd | MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES WITH INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF |
-
2003
- 2003-09-08 US US10/658,834 patent/US7611700B2/en active Active
- 2003-09-08 AU AU2003263552A patent/AU2003263552A1/en not_active Abandoned
- 2003-09-08 WO PCT/IB2003/004347 patent/WO2004022593A2/en not_active Application Discontinuation
- 2003-09-08 DE DE60332358T patent/DE60332358D1/en not_active Expired - Lifetime
- 2003-09-08 EP EP03794017A patent/EP1539960B1/en not_active Expired - Lifetime
- 2003-09-08 CA CA002498319A patent/CA2498319A1/en not_active Abandoned
- 2003-09-08 ES ES03794017T patent/ES2343518T3/en not_active Expired - Lifetime
- 2003-09-08 AT AT03794017T patent/ATE466085T1/en not_active IP Right Cessation
-
2005
- 2005-07-06 US US11/176,830 patent/US20060020116A1/en not_active Abandoned
-
2007
- 2007-01-22 US US11/656,921 patent/US20070254838A1/en not_active Abandoned
- 2007-02-06 US US11/703,610 patent/US20080075672A1/en not_active Abandoned
- 2007-02-07 US US11/704,141 patent/US20080194477A1/en not_active Abandoned
- 2007-02-13 US US11/706,088 patent/US7998469B2/en not_active Expired - Fee Related
- 2007-02-14 US US11/707,014 patent/US7650243B2/en not_active Expired - Fee Related
- 2007-07-05 US US11/825,604 patent/US20080159977A1/en not_active Abandoned
-
2008
- 2008-04-09 US US12/082,389 patent/US8057787B2/en not_active Expired - Fee Related
- 2008-04-09 US US12/082,365 patent/US8052964B2/en not_active Expired - Fee Related
- 2008-06-06 US US12/157,150 patent/US8114839B2/en not_active Expired - Fee Related
-
2011
- 2011-01-26 US US13/014,392 patent/US8105573B2/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8052964B2 (en) | 2002-09-09 | 2011-11-08 | Hanall Biopharma Co., Ltd. | Interferon-β mutants with increased anti-proliferative activity |
US8057787B2 (en) | 2002-09-09 | 2011-11-15 | Hanall Biopharma Co., Ltd. | Protease resistant modified interferon-beta polypeptides |
US8105573B2 (en) | 2002-09-09 | 2012-01-31 | Hanall Biopharma Co., Ltd. | Protease resistant modified IFN beta polypeptides and their use in treating diseases |
US8114839B2 (en) | 2002-09-09 | 2012-02-14 | Hanall Biopharma Co., Ltd. | Protease resistant modified erythropoietin polypeptides |
US7884073B2 (en) | 2004-11-04 | 2011-02-08 | Hanall Biopharma Co., Ltd. | Modified growth hormone |
US8252743B2 (en) | 2006-11-28 | 2012-08-28 | Hanall Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
JP7050007B2 (en) | 2016-06-08 | 2022-04-07 | ヤンセン バイオテツク,インコーポレーテツド | GM-CSF mutant and usage |
Also Published As
Publication number | Publication date |
---|---|
US20080075672A1 (en) | 2008-03-27 |
US8052964B2 (en) | 2011-11-08 |
US20070254838A1 (en) | 2007-11-01 |
US20040132977A1 (en) | 2004-07-08 |
US20060020116A1 (en) | 2006-01-26 |
US20110142801A1 (en) | 2011-06-16 |
EP1539960A2 (en) | 2005-06-15 |
US8057787B2 (en) | 2011-11-15 |
US20080159977A1 (en) | 2008-07-03 |
US20090131318A1 (en) | 2009-05-21 |
WO2004022593A3 (en) | 2004-07-15 |
CA2498319A1 (en) | 2004-03-18 |
ATE466085T1 (en) | 2010-05-15 |
US20090053147A1 (en) | 2009-02-26 |
US7650243B2 (en) | 2010-01-19 |
US20080194477A1 (en) | 2008-08-14 |
DE60332358D1 (en) | 2010-06-10 |
US7611700B2 (en) | 2009-11-03 |
US20090123974A1 (en) | 2009-05-14 |
US8105573B2 (en) | 2012-01-31 |
ES2343518T3 (en) | 2010-08-03 |
AU2003263552A8 (en) | 2004-03-29 |
EP1539960B1 (en) | 2010-04-28 |
US20070224665A1 (en) | 2007-09-27 |
US20080274081A9 (en) | 2008-11-06 |
US7998469B2 (en) | 2011-08-16 |
US8114839B2 (en) | 2012-02-14 |
AU2003263552A1 (en) | 2004-03-29 |
US20070172459A1 (en) | 2007-07-26 |
WO2004022593A2 (en) | 2004-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004022593A8 (en) | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules | |
EP1624065A3 (en) | Agarase and gene thereof | |
AU2003252111A1 (en) | Fluorescent proteins, nucleic acids encoding them and methods for making and using them | |
WO2003066879A3 (en) | Amino acid transporters | |
AU2002258630A1 (en) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof | |
WO2002079384A9 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002303137A1 (en) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof | |
AU2002257075A1 (en) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof | |
WO2003016465A3 (en) | Cell cycle regulator protein | |
AU2003284579A1 (en) | PROTEIN FORMING COMPLEX WITH c-Fos PROTEIN, NUCLEIC ACID ENCODING THE SAME AND METHOD OF USING THE SAME | |
AU2002258618A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2003215179A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and used thereof | |
AU2003222241A1 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
AU2003209105A1 (en) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof | |
AU2002311750A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002303180A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002258629A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002314731A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002305909A1 (en) | Isolated human transporter protein, nucleic acid molecules encoding human transporter protein, and uses thereof | |
AU2003225666A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2003220013A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2003215212A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002240295A1 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
AU2003225626A1 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
AU2003221757A1 (en) | Nucleic acid molecules encoding human proteins, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2498319 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003794017 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003794017 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |